Celldex CDX-1127 data positive, says Oppenheimer After analyzing ASCO abstracts, Oppenheimer thinks the data indicated that Celldex's CDX-1127 is well-tolerated and capable of inducing an immune response. The firm keeps an Outperform rating on the stock.
Celldex appoints Richard Wright as Chief Commercial Officer Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.